Suppr超能文献

医疗补助扩张与皮肤黑色素瘤诊断和结局的关联:居住地的不同是否会产生影响?

Association between Medicaid Expansion and Cutaneous Melanoma Diagnosis and Outcomes: Does Where You Live Make a Difference?

机构信息

Department of Surgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.

Division of Surgical Oncology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.

出版信息

Ann Surg Oncol. 2024 Jul;31(7):4584-4593. doi: 10.1245/s10434-024-15214-y. Epub 2024 Mar 29.

Abstract

BACKGROUND

Early detection and standardized treatment are crucial for enhancing outcomes for patients with cutaneous melanoma, the commonly diagnosed skin cancer. However, access to quality health care services remains a critical barrier for many patients, particularly the uninsured. Whereas Medicaid expansion (ME) has had a positive impact on some cancers, its specific influence on cutaneous melanoma remains understudied.

METHODS

The National Cancer Database identified 87,512 patients 40-64 years of age with a diagnosis of non-metastatic cutaneous melanoma between 2004 and 2017. In this study, patient demographics, disease characteristics, and treatment variables were analyzed, and ME status was determined based on state policies. Standard univariate statistics were used to compare patients with a diagnosis of non-metastatic cutaneous melanoma between ME and non-ME states. The Kaplan-Meier method and log-rank tests were used to evaluate overall survival (OS) between ME and non-ME states. Multivariable Cox regression models were used to examine associations with OS.

RESULTS

Overall, 28.6 % (n = 25,031) of the overall cohort was in ME states. The patients in ME states were more likely to be insured, live in neighborhoods with higher median income quartiles, receive treatment at academic/research cancer centers, have lower stages of disease, and receive surgery than the patients in non-ME states. Kaplan-Meier analysis found enhanced 5-year OS for the patients in ME states across all stages. Cox regression showed improved survival in ME states for stage II (hazard ratio [HR], 0.84) and stage III (HR, 0.75) melanoma.

CONCLUSIONS

This study underscores the positive association between ME and improved diagnosis, treatment, and outcomes for patients with non-metastatic cutaneous melanoma. These findings advocate for continued efforts to enhance health care accessibility for vulnerable populations.

摘要

背景

早期发现和标准化治疗对于提高皮肤黑色素瘤患者的治疗效果至关重要,皮肤黑色素瘤是最常见的皮肤癌。然而,对于许多患者,尤其是没有保险的患者来说,获得高质量的医疗保健服务仍然是一个关键障碍。尽管医疗补助扩展(ME)对某些癌症产生了积极影响,但它对皮肤黑色素瘤的具体影响仍有待研究。

方法

国家癌症数据库确定了 87512 名年龄在 40-64 岁之间的非转移性皮肤黑色素瘤患者,这些患者的诊断时间在 2004 年至 2017 年之间。在这项研究中,分析了患者的人口统计学特征、疾病特征和治疗变量,并根据州政策确定了 ME 状态。使用标准单变量统计方法比较了 ME 州和非 ME 州患有非转移性皮肤黑色素瘤的患者。使用 Kaplan-Meier 方法和对数秩检验评估 ME 州和非 ME 州之间的总生存期(OS)。使用多变量 Cox 回归模型来检查与 OS 相关的因素。

结果

总体而言,28.6%(n=25031)的患者处于 ME 州。与非 ME 州的患者相比,ME 州的患者更有可能有保险,居住在中位数收入较高的社区,在学术/研究癌症中心接受治疗,疾病分期较低,接受手术治疗。Kaplan-Meier 分析发现,在所有分期中,ME 州的患者 5 年 OS 提高。Cox 回归显示,ME 州的 II 期(风险比 [HR],0.84)和 III 期(HR,0.75)黑色素瘤患者的生存率得到改善。

结论

这项研究强调了 ME 与改善非转移性皮肤黑色素瘤患者的诊断、治疗和结局之间的积极关联。这些发现主张继续努力提高弱势群体的医疗保健可及性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验